| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2022/06/16 | 00 : 36 | Edgar (US Regulatory) | Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/06/09 | 20 : 10 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/06/09 | 10 : 16 | Business Wire | Alvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum Unternehmenszusammenschluss | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/06/08 | 18 : 54 | Business Wire | Alvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprises | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/06/08 | 05 : 00 | Business Wire | Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/06/04 | 06 : 29 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/06/04 | 06 : 17 | Business Wire | Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/06/01 | 06 : 19 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/24 | 20 : 24 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/24 | 20 : 00 | Business Wire | Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara® | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/17 | 22 : 00 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/17 | 04 : 08 | Edgar (US Regulatory) | Quarterly Report (10-q) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/16 | 21 : 07 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/16 | 21 : 00 | Business Wire | Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara® | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/11 | 21 : 00 | Business Wire | Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/05/11 | 07 : 34 | Edgar (US Regulatory) | Proxy Statement - Merger or Acquisition (definitive) (defm14a) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/23 | 05 : 31 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/21 | 06 : 00 | Business Wire | Alvotech améliore son accès aux capitaux et optimise son processus d’entrée en bourse, prévue sur le NASDAQ | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/21 | 01 : 45 | Business Wire | Alvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-Notierung | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/20 | 21 : 15 | Business Wire | Alvotech migliora l'accesso al capitale e semplifica il percorso verso la prevista quotazione in Borsa al NASDAQ | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/20 | 07 : 00 | Business Wire | Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/20 | 06 : 26 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/19 | 06 : 12 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/08 | 23 : 01 | Business Wire | アルヴォテックとSTADA、アッヴィとの欧州特許紛争を解決してHumira®のクエン酸フリー高濃度バイオシミラーHUKYNDRA®（AVT02）発売への道を開く | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/07 | 10 : 15 | Business Wire | Alvotech et STADA ouvrent la voie au lancement de HUKYNDRA® (AVT02), un biosimilaire de l'Humira® haute concentration sans citrate, en réglant le litige de brevet européen qui les opposait à AbbVie | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/07 | 07 : 21 | Business Wire | Alvotech und STADA ebnen durch Beilegung des europäischen Patentstreits mit AbbVie den Weg für die Markteinführung von HUKYNDRA®(AVT02), einem zitratfreien, hochkonzentrierten Biosimilar zu Humira® | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/06 | 20 : 51 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/04/06 | 20 : 00 | Business Wire | Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/03/24 | 05 : 20 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NYSE:OACB | Oaktree Acquisition Corp II |
| 2022/03/14 | 20 : 10 | Business Wire | アルヴォテックがアッヴィとの米国特許・企業秘密紛争を解決し、Humira®向けにアルヴォテックが提案中の高濃度バイオシミラー（AVT02）の米国での権利を確保 | NYSE:OACB | Oaktree Acquisition Corp II |